▲ bullish
ImpactNot rated
PhaseNot stated
Time to marketNot stated
| Date | Drug | Event | 1 day |
|---|---|---|---|
| Mar 26, 2026 | IMCIVREE | Approval | −10.4% |
| Mar 20, 2026 | IMCIVREE | PDUFA decision | −6.3% |
| Mar 19, 2026 | IMCIVREE | Approval | +1.9% |
| Dec 20, 2025 | IMCIVREE | PDUFA decision | +0.7% |
| Dec 20, 2025 | IMCIVREE | Priority review | +0.7% |
| Aug 20, 2025 | IMCIVREE | NDA filed | +4.6% |
| Aug 20, 2025 | IMCIVREE | Priority review | +4.6% |
| Nov 25, 2020 | IMCIVREE | Approval | +26.2% |
| Trial | Status | Primary completion |
|---|---|---|
| Open-Label Extension Study of Setmelanotide | Completed | Jun 24, 2026 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Completed · results | Feb 9, 2026 |
| EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Completed · results | Dec 19, 2025 |